根据最近的研究, Wegovy与肥胖致癌风险降低39%有关。 Weight-loss drug Wegovy linked to 39% reduction in obesity-related cancer risk, per recent studies.

根据最近的研究,Wegovy(GLP-1药物)等重量损失药物可能有助于预防与肥胖有关的癌症。 Weight-loss drugs like Wegovy (GLP-1 drugs) may help prevent obesity-related cancers, according to recent studies. 与胰岛素治疗相比,这些药物可为糖尿病患者提供更多的防癌保护,并可以将肥胖致癌风险降低39%,即使患者没有大量减重。 These drugs may provide more protection against cancer for diabetic patients than insulin treatments and can reduce obesity-related cancer risk by 39%, even when patients do not lose a significant amount of weight. GLP-1药物可能利用多种体能机制来减少易患癌症的可能性,例如更好地控制淋病和抗炎效果。 GLP-1 drugs may act on multiple body mechanisms to reduce vulnerabilities to cancer, such as better glycemic control and anti-inflammatory effects.